Insilico Medicine's shares rose 24.7% in their Hong Kong trading debut on December 30, 2025, reaching a market cap of $2.1 billion. The AI drug discovery company raised $293 million in its IPO, drawing cornerstone investors including Eli Lilly, Tencent, and Temasek.
Alex Zhavoronkov, Insilico’s founder, CEO and CBO, as well as head of LongeVC advisory board, leads the company's mission to use AI to accelerate drug discovery and become a major source of innovative drugs for pharma companies. The IPO proceeds will fund R&D for clinical-stage candidates, develop new generative AI models, and expand robotic laboratory capabilities.
Read the full article here.
Alex Zhavoronkov, Insilico’s founder, CEO and CBO, as well as head of LongeVC advisory board, leads the company's mission to use AI to accelerate drug discovery and become a major source of innovative drugs for pharma companies. The IPO proceeds will fund R&D for clinical-stage candidates, develop new generative AI models, and expand robotic laboratory capabilities.
Read the full article here.